MyndLink: AI-Powered Intelligence for Transforming Neurological Treatment

MyndLink™ is an AI-powered therapy assistant fueled by agentic reasoning listening frameworks that maximizes neurological treatment outcomes by providing real-time, data-driven recommendations with predictive analytics and automated data. For stroke and spinal cord injury rehabilitation, it helps healthcare providers optimize treatment protocols for the 60-70% of stroke survivors who experience persistent upper limb impairment 1, 2, 3 despite 850,000 annual cases in North America 4. For chronic pain management, it helps providers select patients most likely to benefit from spinal cord stimulation (SCS) therapy, reducing the high failure rate of 25-30% 5. In the U.S., over 50,000 SCS procedures are performed annually 6.; 15,000 cases will likely fail 5., as a result of improper or subjective patient selection and a trial-and-error approach. By predicting which treatments and patients will benefit most, MyndLink improves outcomes and lowers healthcare costs by minimizing unsuccessful procedures.

Market Facts

Stroke & Spinal Cord Injury Rehabilitation: The North American FES/Neurorehabilitation market is valued at $5B – $6B+ with an 8% CAGR through 2032 7.. The market is driven by 850,000 annual stroke cases 4. and 18,000 new spinal cord injury cases 8. annually, distributed among approximately 1,250 Inpatient Rehabilitation Facilities and 17,000 Outpatient Neuro/Rehab Clinics 9..
Chronic Pain / Spinal Cord Stimulation: The global SCS market is expected to grow to $4.12 billion by 2027 with an 8.0% growth rate 10., driven by the rise in chronic pain, aging populations, and demand for minimally invasive treatments. The North America market represented 73% of the market share in 2023, representing a growth of 3 billion by 2027, distributed among hospitals, ambulatory surgery centers and specialty clinics 10..

How It Works:

  • MyndLink analyzes each patient’s unique medical profile and treatment history
  • AI algorithms determine the most effective treatment path and predict outcomes
  • Healthcare providers receive clear insights, enabling personalized care tailored to each patient’s needs.

Revolutionizing Neurological Treatment:

  • Stroke & SCI Rehabilitation: MyndLink predicts optimal treatment protocols, automates clinical documentation, and provides objective outcome data for value-based care.
  • Chronic Pain Treatment: Ending the Guesswork in Spinal Cord Stimulation—MyndLink predicts which patients will respond positively to SCS therapy.
  • MyndLink: Transforming Neurological Treatment Across Multiple Conditions

Note: MyndLink is in development; its safety and effectiveness has not yet been established or approved by the FDA. Primary development focus: Stroke and spinal cord injury rehabilitation (2026-2028). Chronic pain applications represent early-stage research exploration.

  1. PMC Rehabilitation Study (2022) – https://pmc.ncbi.nlm.nih.gov/articles/PMC8872602/
  2. Vivistim Upper Limb Impairment Review (2022) – https://www.vivistim.com/life-after-stroke-3-facts-you-should-know-about-upper-limb-impairment/
  3. ACNR Journal (2019) – https://acnr.co.uk/articles/an-expert-opinion-upper-limb-rehabilitation-after-stroke/
  4. American Heart Association, 2024 Heart Disease & Stroke Statistics; CDC Stroke Facts 2024
  5. Dougherty, M. C., et al. (2021). Risk Factors and Survival Analysis of Spinal Cord Stimulator Explantation. Neuromodulation, 24(1), 61–67. https://doi.org/10.1111/ner.13173
  6. 2025 American Academy of Family Physicians – Despite weak evidence, spinal cord stimulators are big business
  7. Grand View Research, Neurorehabilitation Devices Market Report 2024
  8. National Spinal Cord Injury Statistical Center, 2024 SCI Facts and Figures
  9. CMS Provider Data; Newsweek/Statista Physical Rehabilitation Centers Rankings 2024
  10. Fortune Business Insights, 2025 – SCS Market Size, Share and Regional Forecast 2020-2027